Publications by authors named "Chitomi Hasebe"

Claim this Profile
S
Sofosbuvir/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings.
Hitomi Takada, Nobuharu Tamaki, Hironori Ochi, Nami Mori, Keiji Tsuji, Chitomi Hasebe

Intern Med· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis.
Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Chitomi Hasebe

J Gastroenterol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy.
Toshifumi Tada, Masayuki Kurosaki, Hidenori Toyoda, Nobuharu Tamaki, Yutaka Yasui, Chitomi Hasebe

Liver Int· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants.
Yoshihiro Kamada, Hideki Fujii, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Chitomi Hasebe

Gastro Hep Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study.
Atsuhiro Morita, Nobuharu Tamaki, Haruhiko Kobashi, Nami Mori, Keiji Tsuji, Chitomi Hasebe

JGH Open· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large-scale multicenter retrospective study.
Hideki Fujii, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Chitomi Hasebe

Hepatol Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response.
Shun Ishido, Nobuharu Tamaki, Masayuki Kurosaki, Nami Mori, Keiji Tsuji, Chitomi Hasebe

JGH Open· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
Shintaro Takaki, Masayuki Kurosaki, Nami Mori, Keiji Tsuji, Hironori Ochi, Chitomi Hasebe

Invest New Drugs· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Hironori Ochi, Masayuki Kurosaki, Kouji Joko, Toshie Mashiba, Nobuharu Tamaki, Chitomi Hasebe

Hepatol Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Nobuharu Tamaki, Toshifumi Tada, Masayuki Kurosaki, Yutaka Yasui, Hironori Ochi, Chitomi Hasebe

Invest New Drugs· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
Toshie Mashiba, Kouji Joko, Masayuki Kurosaki, Hironori Ochi, Hiroyuki Marusawa, Chitomi Hasebe

J Viral Hepat· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy.
Toshifumi Tada, Masayuki Kurosaki, Nobuharu Tamaki, Yutaka Yasui, Nami Mori, Chitomi Hasebe

JGH Open· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.
Yutaka Yasui, Masayuki Kurosaki, Kaoru Tsuchiya, Yuka Hayakawa, Chitomi Hasebe

Cancers (Basel)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world long-term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection.
Hideki Fujii, Hiroyuki Kimura, Chitomi Hasebe, Takehiro Akahane, Takashi Satou

JGH Open· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus.
Nobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, Nami Mori, Keiji Tsuji, Chitomi Hasebe

Hepatol Commun· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response.
Toshifumi Tada, Masayuki Kurosaki, Nobuharu Tamaki, Yutaka Yasui, Nami Mori, Chitomi Hasebe

JGH Open· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
Nobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, Nami Mori, Keiji Tsuji, Chitomi Hasebe

Clin Infect Dis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Toshifumi Tada, Masayuki Kurosaki, Shinichiro Nakamura, Chitomi Hasebe, Yuji Kojima

J Med Virol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
Kaoru Tsuchiya, Masayuki Kurosaki, Azusa Sakamoto, Hiroyuki Marusawa, Yuji Kojima, Chitomi Hasebe

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C.
Jun Itakura, Masayuki Kurosaki, Satoru Kakizaki, Keisuke Amano, Nobuaki Nakayama, Chitomi Hasebe

JHEP Rep· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score.
Shun Kaneko, Masayuki Kurosaki, Kouji Joko, Hiroyuki Marusawa, Masahiko Kondo, Chitomi Hasebe

Sci Rep· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group.
Toshie Mashiba, Kouji Joko, Masayuki Kurosaki, Hironori Ochi, Chitomi Hasebe

Hepatol Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
Goki Suda, Chitomi Hasebe, Masami Abe, Masayuki Kurosaki, Jun Itakura

J Gastroenterol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Takehiro Akahane, Masayuki Kurosaki, Jun Itakura, Keiji Tsuji, Kouji Joko, Chitomi Hasebe

Hepatol Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
Goki Suda, Masayuki Kurosaki, Jun Itakura, Namiki Izumi, Yoshihito Uchida, Chitomi Hasebe

J Gastroenterol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis